PEOPLE - Affibody makes appointment:
This article was originally published in Clinica
Stockholm-based Swedish biotech firm Affibody has promoted Ulf Boberg to CEO. Dr Boberg, who joined the firm in January 2006 as senior vice-president for development, replaces acting CEO Dr Carl-Johan Dalsgaard, who will remain a non-executive board member. Dr Boberg's 18 years' experience in the industry include several leading and financial roles, most recently as CEO of Global Genomics AB. Other positions include: senior VP and head of the development division of Astra Pain Control; investment manager of LinkMed AB; and head of Medical Research at Gambro.